Gilead Sciences (NASDAQ:GILD) Price Target Raised to $100.00

Gilead Sciences (NASDAQ:GILD) had its target price raised by Mizuho from $90.00 to $100.00 in a report released on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of 12.83% from the stock’s previous close.

Several other equities analysts also recently commented on the stock. BMO Capital Markets increased their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday. Citigroup assumed coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective on the stock. Cantor Fitzgerald upped their target price on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Finally, Wolfe Research assumed coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective for the company. Twelve analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $94.45.

Gilead Sciences Trading Up 1.0 %

NASDAQ:GILD opened at $88.63 on Thursday. The stock has a market cap of $110.46 billion, a PE ratio of 984.78, a price-to-earnings-growth ratio of 2.72 and a beta of 0.17. Gilead Sciences has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock’s 50-day moving average is $87.15 and its two-hundred day moving average is $76.52.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the business earned $2.29 EPS. As a group, equities research analysts forecast that Gilead Sciences will post 4.38 earnings per share for the current fiscal year.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock valued at $4,968,674 in the last 90 days. 0.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds have recently bought and sold shares of the company. MQS Management LLC bought a new stake in Gilead Sciences in the first quarter valued at $250,000. Axxcess Wealth Management LLC raised its position in shares of Gilead Sciences by 24.5% during the first quarter. Axxcess Wealth Management LLC now owns 17,916 shares of the biopharmaceutical company’s stock worth $1,312,000 after purchasing an additional 3,521 shares during the period. Canada Pension Plan Investment Board lifted its holdings in shares of Gilead Sciences by 6.1% in the 1st quarter. Canada Pension Plan Investment Board now owns 1,410,443 shares of the biopharmaceutical company’s stock worth $103,315,000 after purchasing an additional 80,666 shares in the last quarter. Epoch Investment Partners Inc. grew its position in Gilead Sciences by 18.7% in the 1st quarter. Epoch Investment Partners Inc. now owns 887,978 shares of the biopharmaceutical company’s stock valued at $65,044,000 after purchasing an additional 139,907 shares during the period. Finally, Lazard Asset Management LLC increased its stake in Gilead Sciences by 2.6% during the 1st quarter. Lazard Asset Management LLC now owns 969,733 shares of the biopharmaceutical company’s stock valued at $71,032,000 after purchasing an additional 24,683 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.